

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

CELLTRION, INC.,  
Petitioner,

v.

GENENTECH, INC.,  
Patent Owner.

---

Case IPR2017-01373  
U.S. Patent 6,407,213

---

**DECLARATION OF ANDREW J. DANFORD IN SUPPORT OF  
MOTION FOR ADMISSION *PRO HAC VICE***

I, Andrew J. Danford, declare as follows:

1. I was admitted to the Massachusetts Bar in January of 2009 and the New York Bar in August of 2010 and have been practicing law for over 7 years. During the entire time that I have been practicing law, my practice has focused on the field of intellectual property, and particularly, patent litigation.
2. I am a member in good standing of the Massachusetts and New York Bars, and am admitted to practice before the United States District Court for the District of Massachusetts, the United States Court of Appeals for the First Circuit, and the United States Court of Appeals for the Federal Circuit.
3. My New York Bar membership number is 4855318. My Massachusetts Bar membership number is 672342.
4. Over the course of my career, I have been counsel in numerous patent litigations. Several of these cases have concerned Patent Office rules and regulations. For example, I represented Cephalon, Inc. in *Apotex Inc. v. Cephalon, Inc.*, No. 12-1417 (Fed. Cir.).
5. I have never been suspended or disbarred from practice before any court or administrative body.

6. I have never had a court or administrative body deny my application for admission to practice.
7. I have never had any sanctions or contempt citations imposed on me by any court or administrative body.
8. I have read and will comply with Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.
9. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
10. I represent Patent Owner Genentech, Inc. in a number of pending IPR proceedings, including IPR2017-00731 (institution denied July 27, 2017, request for rehearing filed August 25, 2017; *pro hac vice* granted October 2, 2017; instituted October 26, 2017, pending); IPR2017-00737 (*pro hac vice* granted June 21, 2017, pending); IPR2017-00739 (*pro hac vice* granted June 21, 2017; institution denied July 27, 2017); IPR2017-00804 (*pro hac vice* granted October 2, 2017, pending); IPR2017-00805 (*pro hac vice* granted October 2, 2017, pending); IPR2017-01121 (*pro hac vice* granted, October 30, 2017, pending); IPR2017-01122 (*pro hac vice* granted, October 30, 2017, pending); IPR2017-01139 (*pro hac vice* granted October 30, 2017, pending); IPR2017-01140 (*pro hac vice* motion granted October 30, 2017,

pending); IPR2017-01374 (*pro hac vice* motion to be filed, pending);  
IPR2017-01488 (*pro hac vice* granted September 27, 2017, pending);  
IPR2017-01489 (*pro hac vice* granted September 27, 2017, pending);  
IPR2017-01726 (*pro hac vice* motion to be filed, pending); IPR2017-01727  
(*pro hac vice* motion to be filed, pending); IPR2017-01958 (*pro hac vice*  
motion to be filed; pending); IPR2017-01959 (*pro hac vice* motion to be  
filed, pending); IPR2017-01960 (joined to IPR2017-00737); IPR2017-02031  
(*pro hac vice* to be filed, pending); IPR2017-02032 (*pro hac vice* to be filed,  
pending); IPR2017-02063 (*pro hac vice* to be filed, pending); IPR2017-  
02139 (*pro hac vice* to be filed, pending); IPR2017-02140 (*pro hac vice* to  
be filed, pending); IPR2018-00016 (*pro hac vice* to be filed, pending);  
IPR2018-00192 (*pro hac vice* to be filed, pending). I have also assisted  
Patent Owner Genentech, Inc. in a number of IPR proceedings, including  
IPR2015-01624, which was terminated due to settlement; IPR2016-00710,  
which was terminated due to settlement; IPR2016-01373, which was not  
instituted; IPR2016-00460, which was joined with IPR2015-01624 (which  
was terminated due to settlement); IPR2016-00383, which was not  
instituted; and IPR2017-00047, which was joined with IPR2016-00710  
(which was terminated due to settlement). I also assisted Patent Owner  
Genentech, Inc. in IPR2016-01693 (challenging U.S. Patent No. 6,407,213,

that patent at issue in this case) and IPR2016-01694 (challenging U.S. Patent No. 6,407,213, that patent at issue in this case), which were terminated due to settlement.

11. I am intimately familiar with the subject matter of U.S. Patent No. 6,407,213 and the prior art at issue in this proceeding. I am also intimately familiar with antibody technology as a result of my participation in prior antibody-related patent cases such as IPR2015-01624. I have also represented Genentech in prior challenges (IPR2016-01693 and IPR2016-01694) to U.S. Patent No. 6,407,213, the patent at issue in this case. In addition, I have represented life sciences and pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Takeda Pharmaceuticals, AstraZeneca, and Cephalon in patent litigation matters before federal district courts and the Federal Circuit. The technology involved in these disputes includes drugs for a variety of disease conditions, including hyperlipidemia, HIV, hepatitis B, pulmonary diseases, and sleep disorders.
12. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.